Add To Watchlist
Share URL
Neurocrine Biosciences, Inc.
NBIX: NasdaqGSLowest reading is at 46 out of 100. All scores are out of 100.
In Short
About The Company
CEO
Mr. Kyle W. Gano Ph.D.
Market Cap
14.07 Billion USD
Sector
Healthcare
Website
https://www.neurocrine.comLast Update
27/09/2026, 17:22:39
Description
Neurocrine Biosciences, Inc.
Read More
Strongest readings
- ✔Debt is low at 0.11 times equity
- ✔Financial health is strong (health score 77 out of 100)
- ✔Altman-Z score of 5.71 sits above the distress range
Weakest readings
- ✘The current price sits above estimated fair value (margin of safety -73.75%)
- ✘Share count has been rising at 0.33% per year
- ✘Price-to-earnings of 19.6 is above the market average of 19.6
Key Figures
| Status | Metric | Value | Reading | Market avg |
|---|---|---|---|---|
| ✘ | Price / earnings (TTM) | 19.62x | 19.60x | |
| ✘ | Margin of safety (DCF) | -73.75% | 17.95% | |
| ✘ | Revenue growth (5y average) | 5.40% | 10.97% | |
| ✘ | Dividend yield (TTM) | 0.00% | 1.85% | |
| ✘ | Share count, per year | 0.33% | 0.00% | |
| ✘ | Return on capital employed | 3.68% | 10.00% |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
Valuation
57 / 100Priced at or below the market on most measures.
| Status | Metric | Value | Reading | Market avg |
|---|---|---|---|---|
| ✘ | Price / earnings | 19.62x | 19.60x | |
| ✔ | Free cashflow yield | 6.19% | 4.70% | |
| Price / earnings growth | N/A | 1.50x | ||
| Price / book | 3.81x | — | ||
| ✘ | Margin of safety | -73.75% | 17.95% |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
- ✘Estimated intrinsic value of 36.34 USD is below the current price of 138.40 USD
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Estimated Fair Value: 55 USD ✘
Current Price: 138.4 USD
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated fair value for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel for the impact this has on longterm investment returns and find a margin of safety you are comfortable with.
Growth
58 / 100Growing faster than the market on most measures.
| Status | Metric | Value | Reading | Market avg |
|---|---|---|---|---|
| ✘ | Revenue growth | 5.40% | 10.97% | |
| ✔ | Earnings growth | 27.53% | 14.48% | |
| ✘ | Cashflow growth | 9.57% | 12.35% |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
- ✔Revenue growth has improved this year (34.42% against a five year average of 5.40%)
- ✔Earnings growth has improved this year (102.90% against a five year average of 27.53%)
- ✔Free cashflow growth has improved this year
Health
77 / 100Balance sheet covers its obligations.
Measured on Leverage and capital, Funding and liquidity, Earnings quality.
| Status | Metric | Value | Reading | Threshold |
|---|---|---|---|---|
| ✔ | Altman-Z score | 5.71 | 3.00 | |
| ✔ | Piotroski score | 5.00 | 5.00 | |
| ✔ | Debt / equity | 0.11x | 0.80x | |
| ✔ | Current ratio | 1.87x | 1.00x | |
| ✔ | Interest coverage | 56.93x | 2.50x | |
| ✔ | Free cashflow / debt | 0.32x | 0.15x | |
| ✔ | Debt / capital | 0.10x | 1.00x |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
Management
46 / 100Returns on capital are below the market.
| Status | Metric | Value | Reading | Market avg |
|---|---|---|---|---|
| ✘ | Return on equity | 3.91% | 15.00% | |
| ✘ | Return on capital employed | 3.68% | 10.00% | |
| Return on assets | 2.69% | — | ||
| Free cashflow return on capital | 2.87% | — | ||
| ✔ | Return on capital, 5y change | 1.42% | 0.00% | |
| ✘ | Share count, per year | 0.33% | 0.00% | |
| ✘ | Share count, recent | 0.64% | 0.00% | |
| ✘ | Realized buyback return | -97.41% | 0.00% | |
| ✔ | Goodwill erosion / equity | 0.02% | 2.00% | |
| Price volatility, 5 year | 33.63% | — |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
- ✘New shares were issued while the value score was 57 out of 100
Analysts
not enough data| Status | Metric | Value | Reading | Neutral |
|---|---|---|---|---|
| Analyst opinion score | N/A | 50 |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
Financial History
Annual figures across the full reporting history we hold.
Market Peers
NBIX
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
See 35+ Years Annual ReportsOther Information
Company Name
Neurocrine Biosciences, Inc.
Currency
USD
Beta
0.381
Vol Avg
1237019
Ceo
Mr. Kyle W. Gano Ph.D.
Cik
0000914475
Cusip
Exchange
NasdaqGS
Full Time Employees
2500
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Ipo Date
Address
6027 Edgewood Bend Court
City
San Diego
State
CA
Country
United States
Zip
92130
Phone
858 617 7600
Analysis Last Updated
27/09/2026, 17:22:39
Financial data compiled from SEC EDGAR filings and Yahoo Finance.